CAPR Quote, Financials, Valuation and Earnings

Arcturus Therapeutics Holdings, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of -95.02%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98%.

Capricor Therapeutics, Inc. has a consensus price target of $50.80, signalling upside risk potential of 82.67%. On the other hand Arcturus Therapeutics Holdings, Inc. has an analysts' consensus of $35.50 which suggests that it could grow by 443.65%. Given that Arcturus Therapeutics Holdings, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Arcturus Therapeutics Holdings, Inc. is more attractive than Capricor Therapeutics, Inc..

Capricor Therapeutics, Inc. has a beta of 0.614, which suggesting that the stock is 38.632% less volatile than S&P 500. In comparison Arcturus Therapeutics Holdings, Inc. has a beta of 2.102, suggesting its more volatile than the S&P 500 by 110.246%.

Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcturus Therapeutics Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. Arcturus Therapeutics Holdings, Inc. pays out -- of its earnings as a dividend.

Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than Arcturus Therapeutics Holdings, Inc. quarterly revenues of $14.2M. Capricor Therapeutics, Inc.'s net income of -$24.6M is lower than Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while Arcturus Therapeutics Holdings, Inc.'s PE ratio is 8.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 113.42x versus 2.08x for Arcturus Therapeutics Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of -12425.36%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Capricor Therapeutics, Inc. has a consensus price target of $50.80, signalling upside risk potential of 82.67%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 347.55%. Given that Perspective Therapeutics, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Capricor Therapeutics, Inc..

Capricor Therapeutics, Inc. has a beta of 0.614, which suggesting that the stock is 38.632% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Capricor Therapeutics, Inc.'s net income of -$24.6M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 113.42x versus 186.46x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of -30140.49%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat Inovio Pharmaceuticals, Inc.'s return on equity of -252.43%.

Capricor Therapeutics, Inc. has a consensus price target of $50.80, signalling upside risk potential of 82.67%. On the other hand Inovio Pharmaceuticals, Inc. has an analysts' consensus of $7.63 which suggests that it could grow by 234.8%. Given that Inovio Pharmaceuticals, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Inovio Pharmaceuticals, Inc. is more attractive than Capricor Therapeutics, Inc..

Capricor Therapeutics, Inc. has a beta of 0.614, which suggesting that the stock is 38.632% less volatile than S&P 500. In comparison Inovio Pharmaceuticals, Inc. has a beta of 1.544, suggesting its more volatile than the S&P 500 by 54.377%.

Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. Inovio Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than Inovio Pharmaceuticals, Inc. quarterly revenues of --. Capricor Therapeutics, Inc.'s net income of -$24.6M is higher than Inovio Pharmaceuticals, Inc.'s net income of -$45.5M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while Inovio Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 113.42x versus 506.75x for Inovio Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of -36.3%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat Myomo, Inc.'s return on equity of -68.35%.

Capricor Therapeutics, Inc. has a consensus price target of $50.80, signalling upside risk potential of 82.67%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 436.19%. Given that Myomo, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Myomo, Inc. is more attractive than Capricor Therapeutics, Inc..

Capricor Therapeutics, Inc. has a beta of 0.614, which suggesting that the stock is 38.632% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. Capricor Therapeutics, Inc.'s net income of -$24.6M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 113.42x versus 0.92x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.